Noncompliance in randomized controlled trials

Catherine Hewitt and colleagues have given an excellent brief account of the effect of noncompliance on the analysis of randomized controlled trials. We would like to add a few more points to make the discussion more complete.

Noncompliance can seriously decrease study power, resulting in widely varying estimates of the sample size required for a study. Noncompliance is thus a significant issue to be considered when planning trials involving long-term therapies. Moreover, the analysis of results for patients receiving treatment can be biased in situations in which participants decline treatment because they cannot afford to pay for their drugs, if they are not provided free of charge. Incorporation of patient preferences into the randomization process will also bias the results. With these practical issues in mind, it would be an interesting exercise to compare the results of well-designed observational studies with those of randomized controlled trials.

Jeevan P. Marasinghe
Registrar in Obstetrics and Gynecology
Faculty of Medicine
University of Peradeniya
Peradeniya, Sri Lanka
A.A.W. Amarasinghe
Psychiatrist
McDonough, Ga.

REFERENCES
1. Hewitt CE, Torgerson DJ, Miles IN. Is there another way to take account of noncompliance in randomized controlled trials? CMAJ 2006;175(4):347.

DOI:10.1503/cmaj.1060189

Novice drivers with attention-deficit hyperactivity disorder

The recent CMAJ lead editorial on the high rate of injuries and deaths among youthful drivers is long overdue. It focuses our attention on potentially modifiable human factors in this important public health epidemic. The latest edition of the CMA driver’s guide includes changes concerning the safety of drivers with attention-deficit hyperactivity disorder (ADHD).

ADHD was first mentioned as a reportable condition in the previous edition of the handbook. In the 2006 edition, physicians are advised to consider treating novice drivers with ADHD with long-acting stimulants, on the basis of a recent meta-analysis examining the effects of a variety of medications used to treat ADHD.

The conclusion from this meta-analysis was that young drivers with ADHD show a normalization of dysfunctional driving behaviours on a driving simulator and during on-the-road driving when they receive treatment with long-acting methylphenidate compared with treatment with other stimulants and nonstimulants.

To our knowledge this is the first time that clinical research has demonstrated that medications improve driving performance in a vulnerable psychiatric population. We applaud the CMA’s decision to incorporate evidence-based findings in their new handbook; recommendations in previous editions were based on the consensus opinion of an expert panel. The new recommendation leads the way for the international public health community to reduce the risks associated with driving for youth with ADHD.

Laurence Jerome
Adjunct Professor of Psychiatry
University of Western Ontario
London, Ont.

REFERENCES

DOI:10.1503/cmaj.1070042

Organ donation after cardiocirculatory death

The Canadian recommendations for organ donation after cardiocirculatory death advocate confirming the irreversibility of cardiocirculatory arrest by the absence of palpable pulses, blood pressure and respiration during a 5-minute period of continuous observation by at least 1 physician. This criterion does not fulfill the prerequisite requirement of irreversibility for the determination of death.

First, autoresuscitation (the spontaneous return of circulatory and neurological function), also known as the Lazarus phenomenon, has been reported after more than 10 minutes of cardiac electric asystole in humans. Second, the presence of electrocardiographic activity without blood pressure (i.e., pulseless electric activity or ventricular fibrillation) does not indicate irreversible cessation of mechanical cardiac activity. Third, the applicability of criteria for organ donation after cardiocirculatory death becomes questionable when artificial circulatory and ventilatory support is resumed after death in order to maintain the viability of abdominal and thoracic organs in potential donors. Extracorporeal circulatory support can lead to the return of neurological function in people who are neurologically intact before cardiac death. Mechanical occlusion of coronary and cerebral circulation has been used to try to prevent reanimation during the organ procurement process, without substantial evidence for its effectiveness.

The timing involved in cardiocirculatory criteria is arbitrary, and the use of such criteria alone to determine death without simultaneous total cessation of all activity in the donor’s brain
(including the brain stem) during procurement circulatory support will not fulfill the “dead donor rule.” It may be necessary to abandon the dead donor rule to permit the recovery of transplantable organs after cardiocirculatory death.

Mohamed Y. Rady
Department of Critical Care Medicine
Joseph L. Verheijde
Department of Physical Medicine and Rehabilitation
Mayo Clinic Hospital
Phoenix, Ariz.

Joan McGregor
Bioethics, Policy and Law Program
School of Life Sciences and
Department of Philosophy
Arizona State University
Tempe, Ariz.

REFERENCES

Breaking bad news

I thank medical student Nir Lipsman for his insightful and touching article on the hospital’s Family Room.1 This room is usually spoken of, if at all, in hushed and sometimes reverent tones, and when one meets with family members and loved ones there, one is generally met with emotions at the polar ends of the emotional spectrum. The physician’s information will lead to either complete devastation or utter elation; there is rarely a reaction in between these extremes.

Attending physicians can learn from Lipsman’s advice to avoid dancing around the truth, something I have seen happen far too often. When I informed a Family Room full of people that their loved one in the intensive care unit would be paralyzed from the neck down for life, I was met not with sobs and grief, but with questions: “What is the next step? What can we do to help? When can he come home to live with us?” Like Lipsman, I never cease to be amazed by the strength and resilience of these families.

Jeff Blackmer
Executive Director, Office of Ethics
Canadian Medical Association
Ottawa, Ont.

REFERENCE
DOI:10.1503/cmaj.1070026

Staffing levels in long-term care facilities

In their recent CMAJ commentary,1,2 Kimberlyn McGrail and associates correctly noted that in British Columbia private and not-for-profit providers of long-term care have different staffing levels at their sites. However, these differences are driven not by type of ownership but by health authority funding level. Funding varies from $130 to $190 per day for each resident even though the facilities care for similar patients, Helfrich describes the current situation, whereas the study we referred to in our commentary was based on data from the mid to late 1990s, before the complex-care patient designation was introduced. Variation in current funding levels cannot be the reason for the differences in quality of care found in that study.

Second, Helfrich argues that the better performance of facilities operated by health authorities must be driven by those facilities’ access to additional staff. This is precisely the point of our commentary. Surely it is quite feasible that different forms of ownership imply different types of access to resources; the important question is whether those resources make a difference. Do multisite not-for-profit facilities do better than single-site facilities because they can share the costs of developing policies and care practices? Or is it because they can share the costs of specialized staff, such as nurse geriatri-